

Grifols successfully completes refinancing of 2027 maturities, further strengthening balance sheet and extending debt profile

- *Successful refinancing of 2027 debt maturities through a €3.1 billion equivalent Term Loan B and a \$2.1 billion revolving credit facility.*
- *Strong demand from global institutional investors, particularly in the U.S., supporting increased transaction size and improved pricing across all tranches.*
- *Combined with the recent €500 million bond redemption, the transaction reduces gross debt and cash interest expense.*
- *No significant debt maturities until October 2028, reinforcing balance sheet strength and financial flexibility.*

Barcelona, Spain, April 14, 2026 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced that it has successfully completed the refinancing of its 2027 debt maturities through a new credit agreement structured as a Term Loan B (TLB), alongside a revolving credit facility. The transaction enhances the company's financial flexibility, extends its debt maturity profile, and reinforces its liquidity position.

The new financing package totals over \$5.3 billion equivalent and is structured across three tranches, including a U.S. dollar-denominated term loan of \$2.00 billion, a euro-denominated tranche of €1.25 billion, and a revolving credit facility with total commitments of approximately \$2.06 billion. The term loans have a maturity of seven years, while the revolving credit facility has a maturity of six and a half years.

The transaction was met with strong demand from a broad base of global institutional investors, with particularly robust participation from U.S. accounts. This allowed for a significant upsizing of the transaction and improved economic terms across both tranches, reflecting increasing confidence in Grifols' financial trajectory and execution.

The U.S. dollar tranche was priced at SOFR + 250 basis points with an original issue discount (OID) of 99.25, while the euro tranche was priced at Euribor + 300 basis points with an OID of 99.75. Both facilities include leverage-based margin step-down mechanisms.

Proceeds from the transaction have been used to fully refinance the company's existing 2027 debt maturities, including the repayment of the 2019 Term Loan B and the redemption of the remaining outstanding 2019 Notes, while also providing additional liquidity to support the Group's development.

Combined with the previously announced €500 million partial redemption of its 7.5% Senior Secured Notes due 2030, the transaction further strengthens Grifols' balance sheet, reducing funded gross debt, lowering cash interest expense and extending its debt maturity profile.

As a result, Grifols has no significant debt maturities until October 2028 and maintains a strong liquidity position.

GRIFOLS

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols focuses on treating conditions centered on six core therapeutic areas: immunology, neurology, pulmonology, hematology, hepatology and intensive care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's most diversified with more than 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 25,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Tel. +34 93 571 00 02

INVESTORS:

Investor Relations & Sustainability

inversores@grifols.com - investors@grifols.com

sostenibilidad@grifols.com – sustainability@grifols.com

Tel. +34 93 571 02 21

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the foreseeable impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or

GRIFOLS

approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.